Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Pentoxifylline: is it useful in multiple sclerosis?].

J M Prieto1, D Dapena, M Lema

  • 1Servicio de Neurología; Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, 15705, España. meprieto@usc.es

Revista De Neurologia
|May 17, 2001
PubMed
Summary

Pentoxifylline (PTX) may reduce initial interferon side effects in multiple sclerosis patients but offers no long-term functional improvement. Further use beyond three months is not supported by this study.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unilateral thalamotomy with high-intensity focused ultrasound in refractory tremor. First results of a public hospital in Spain.

Neurologia·2025
Same author

[XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (II)].

Revista de neurologia·2024
Same author

[XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (I)].

Revista de neurologia·2024
Same author

[Unilateral thalamotomy with high intensity focal ultrasound in patients with refractory essential tremor: a comparative study between patients under and over 70 years of age].

Revista de neurologia·2024
Same author

Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023.

Neurologia·2024
Same author

Progression and treatment of a series of patients with advanced LRRK2-associated Parkinson's disease.

Neurologia·2022

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Pentoxifylline (PTX) is a phosphodiesterase inhibitor with in vitro Th-1 cytokine inhibition.
  • PTX is investigated as a coadjuvant therapy with interferon for multiple sclerosis (MS) to mitigate side effects.
  • The study explores PTX's potential to reduce interferon-induced adverse events in MS patients.

Purpose of the Study:

  • To evaluate the efficacy of PTX in reducing interferon side effects.
  • To assess the impact of PTX on the functional improvement of multiple sclerosis patients.
  • To determine the overall benefit of PTX as an add-on therapy for MS.

Main Methods:

  • A study involving 18 patients with remitting-relapsing multiple sclerosis over 18 months.
  • Nine patients received concurrent PTX and interferon (800 mg/day); nine received interferon alone.

Related Experiment Videos

  • Clinical status was assessed quarterly using the Expanded Disability Status Scale (EDSS) and Neurological Score (NRS).

    • Main Results:

    • No statistically significant improvement in EDSS or NRS scores was observed in either group after 18 months.
    • Patients on PTX experienced fewer initial side effects (fever, myalgia) in the first three months compared to interferon alone.
    • These differences in side effects diminished over time, and PTX caused transient gastralgias and nausea in two patients.

    Conclusions:

    • PTX may be beneficial as a coadjuvant with interferon during the initial three months of treatment for reducing side effects.
    • No functional improvement was observed, suggesting no justification for prolonged PTX use in multiple sclerosis.
    • Further research may be needed to explore specific patient subgroups or treatment durations for potential benefits.